MA-ALLURION-TECHNOLOGIES
6.7.2021 13:02:11 CEST | Business Wire | Press release
Allurion Technologies announced today two major milestones with the launch of the transformed Allurion Weight Loss Program and new worldwide brand for the company and its program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005001/en/
Allurion began commercial sales of its flagship Elipse® Gastric Balloon in 2016. Over the past five years, the company has treated over 50,000 patients across 40 countries. In that time, the company’s weight loss solution has evolved from a single device to a comprehensive program that combines medical, digital, and nutritional approaches to jumpstart weight loss and form lifelong healthy habits.
The new Allurion Program unveiled today features:
- The Allurion® Balloon, rebranded to reflect its synergistic role with other features in the program
- The Allurion® Virtual Care Suite, enabling end-to-end patient management through the Allurion Health Tracker, Connected Scale, and App
- Allurion Insights, offering providers real-time patient analytics and telehealth features
The Allurion Balloon is the world’s first and only procedureless™ medical device for weight loss that leads to 10-15% total body weight loss in approximately 16 weeks. Over 50,000 patients have been treated with the Allurion Balloon, and its re-branding not only reflects its role within the Allurion Program but also device improvements that have been made to optimize the patient and provider experience.
The Allurion Balloon works hand-in-hand with the Allurion® Virtual Care Suite. The Virtual Care Suite includes tools for the patient and the provider to have a 360-degree weight loss experience designed to deliver lifelong results. The patient receives the Allurion Health Tracker, Connected Scale, and App to track, monitor and support their progress while providing real-time data to their healthcare team. Allurion Insights seamlessly integrates this data with the provider and facilitates end-to-end patient management by providing real-time patient analytics and telehealth features.
The new branding launched today includes new messaging, identity, logos, and other design elements that have been incorporated across all products to deliver a consistent and unified experience to patients and providers around the globe.
“The launch of our transformed Allurion Program and our new branding is the culmination of an initiative we began over a year ago to reimagine the future of weight loss and evolve from a company that offers a product to one that offers a revolutionary experience that delivers lifelong results,” said Shantanu Gaur, M.D., co-founder and CEO of Allurion Technologies. “We worked closely with our patients and providers to develop an experience that meets their needs, and we look forward to seeing the positive impact it will have on patient outcomes around the world.”
About Allurion Technologies
Allurion Technologies is dedicated to ending obesity. The Allurion Program is a 360-degree weight loss experience featuring the Allurion Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Connected Scale, Health Tracker, and App, and Allurion Insights. Learn more about Allurion online at www.allurion.com . Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release
Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release
NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
